NEW YORK (GenomeWeb) – Researchers at Purdue University and Tymora Analytical Operations have developed a method for blood- and urine-based phosphoproteomic analysis that they aim to use to detect and manage various cancers.
The approach, which combines a microfluidics-based capture of microvesicles and exosomes with Tymora’s phosphoprotein enrichment reagents, could allow researchers to profile tumor signaling pathways via blood or urine samples, similar to how liquid biopsies make use of ctDNA analysis, said Tymora President and CTO Anton Iliuk.
Protein phosphorylation is one of the primary vehicles for cellular signaling and, as such, are a major area of focus for cancer research and drug development. Agents that inhibit kinases, the enzymes responsible for protein phosphorylation, are one of the main classes of targeted cancer therapies, and a number of research groups are exploring the use of phosphoproteomics analysis to aid selection of patient treatments and track their response to therapy.
For instance, at MD Anderson Cancer Center, researcher Gordon Mills is using reverse-phase protein arrays to profile cancer signaling pathways in tens of thousands of patients with the goal of identifying patient subtypes and therapies.
Emanuel Petricoin, co-director of the Center for Applied Proteomics and Molecular Medicine at George Mason